This webinar takes place on Thursday September 18th between 16.00 and 16.45 CEST / 15.00-15.45 BST / 10.00-10.45 AM EST / 7.00-7.45 AM PST.

Follow the link to register for the webinar. Please note that the presentation will be given during the live event only and on demand viewing at a later date will not be possible. Contact us for any questions.

 

REGISTER FOR LIVE WEBINAR

 

THIS WEBINAR IS ARRANGED BY CELLECTRICON AB. FOR MORE INFORMATION ON THE HANDLING OF YOUR PERSONAL INFORMATION, SEE OUR PRIVACY POLICY.

Abstract:

Human genomic approaches are identifying more and more genes that are associated with chronic pain. For many of these genes, the physiological association to chronic pain is not self-evident. Furthermore, methods to efficiently validate such targets functionally are currently lacking.

In this webinar, we will glance at Orion’s approach for identification and prioritization of genetically associated pain targets in their Drug Discovery programs. Furthermore, we will present how the combination of lentiviral knock-down (KD) and high-capacity electrophysiology could be used to functionally validate pain targets. In the latter part, we will share data from a proof-of-concept (PoC) study where neuronal excitability (a key hallmark of pain) was evaluated after KD of genetically linked pain targets, e.g. Nav1.7. After the positive outcome of the PoC, the methodology was applied to screen novel pain targets. We will end by discussing how the outcome aided in enabling Orion to rank and prioritize between these targets.

CBO, Cellectricon AB

Paul Karila

Paul joined the company in 2012 as head of Cellectricon’s Discovery Services and is now responsible for deal-making and business development in his role as CBO. He previously worked at AstraZeneca (AZ) where he held leadership positions at the Departments of Molecular Pharmacology and Neuroscience. At AZ, Paul led teams responsible for target identification/target validation and ion channel and GPCR profiling in LI-LO phase, mainly in chronic pain and neuropsychiatry projects. Prior to joining AZ, Paul was a Postdoctoral Fellow at School of Medicine, University of Pittsburgh, USA, studying neurobiology using electrophysiological methods. He has a PhD in physiology from University of Gothenburg, Sweden.
Senior Scientist, Orion Corporation

Lauri Louhivuori

Dr. Louhivuori is a senior scientist at Orion Pharma with over 20 years of experience in the field of neuroscience. He has a Ph.D. in Physiology from the Medical Faculty at the University of Helsinki and did his postdoctoral training at the Karolinska Institute in the Department of Medical Biology and Biophysics. His expertise in electrophysiological, functional imaging and omics approaches have been fundamental to understanding the neurophysiological underpinnings of human pathological states and the quest to discover novel and safe analgesic targets.